A new approach for immunotherapy in neuroblastoma using immunogenic dead cell induced by doxorubicin
| Project/Area Number |
22591984
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Pediatric surgery
|
|---|
| Research Institution | Saitama Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2012: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2010: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 小児腫瘍学 / 腫瘍免疫 / 自然免疫 / 小児固形腫瘍 / apoptosis / 神経芽腫 / 腫瘍ワクチン / 抗原提示 / 外科学 / 小児外科学 / 免疫学 / Apoptosis |
|---|
| Research Abstract |
Doxorubicin can induce immunogenic apoptotic cell death in the neuroblastoma cells, and thus has an immunological advantage in chemotherapy of neuroblastoma. BM -DC is considered to be the key antigen presenting cell in the immune reaction after immunogenic apoptotic neuroblastoma cell phagocytosis. These mechanisms could be able to apply for developing new vaccine therapy for advanced neuroblastoma.
|
Report
(4 results)
Research Products
(6 results)
